Benjamin Ebert, MD, PhD
Harvard Medical School
The primary focus of the Ebert laboratory is the biology and treatment of clonal hematopoiesis and myeloid malignancies. Our genetic studies have led to the characterization of clonal hematopoiesis of indeterminate potential (CHIP) and the identification of mutations in MDS that predict overall survival, outcome following bone marrow transplantation, malignancies to validate candidate therapies. Studies of the mechanism of action of lenalidomide, a drug with efficacy in MDS, revealed that lenalidomide and related compounds act by modulating the function of an E3 ubiquitin ligase, resulting in the drug-induced degradation of key therapeutic targets in hematologic malignancies.
Benjamin Ebert is a Professor of Medicine at Harvard Medical School, an Institute Member of the Broad Institute, and Leader of the Leukemia Program for the Dana-Farber/Harvard Cancer Center. He received a bachelor's degree from Williams College, a doctorate from Oxford University on a Rhodes Scholarship, and an M.D. from Harvard Medical School. He completed a residency in internal medicine at Massachusetts General Hospital and a fellowship in hematology/oncology at the Dana-Farber Cancer Institute.